AOTMiT: The Transparency Council will evaluate drugs, incl. for chronic lymphocytic leukemia and kidney cancer
Published Feb. 1, 2022 10:16
Źródło: AOTMiT
The agenda of the Republic of Poland on February 7 includes:
Preparation of a position on drug evaluation:
Imbruvica (ibrutinibum) under the drug scheme: B.92. "Treatment of patients with chronic lymphocytic leukemia with ibrutinib (ICD-10: C91.1),
Opdivo (nivolumabum) as part of the drug program: "Treatment of inoperable, recurrent or metastatic squamous cell carcinoma of the esophagus (ICD-10 C15)",
Opdivo (nivolumabum) as part of the drug program: B.10. "Treatment of kidney cancer (ICD-10 C64)" in the third line of treatment.
Preparation of an opinion on the active substance cabozantinib used as monotherapy in the treatment of hepatocellular carcinoma (HCC) in adults after unsuccessful treatment with tyrosine kinase inhibitors or immunotherapy in combination with anti-angiogenic therapy or its intolerance, provided that clinically significant adverse effects of the previous therapy are resolved.
Assessment of drug technologies in terms of their innovation.
Source: AOTMiT
